The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice.

Mol Med Rep · 2019 · PMC6854585 · PMID 31638166

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

However, the p-STAT1 levels revealed a decreasing trend at the 48-h time point, indicating that the JAK1/STAT1 pathway plays an important role in the progression and development of ConA-induced acute liver injury in mice.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.